Intravitreal daunomycin induces multidrug resistance in proliferative vitreoretinopathy

Investigative Ophthalmology and Visual Science

Volumn 39, Issue 1, 1998, Pages 164-170

  Esser, Peter ^a   Tervooren, Daniel ^a   Heimann, Klaus ^a   Kociok, Norbert ^a   Bartz Schmidt, Karl Ulrich ^a   Walter, Peter ^a   Weller, Michael ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CRYSTAL VIOLET; CYTOKERATIN; DAUNORUBICIN; FLUOROURACIL; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOPROTEIN P; MESSENGER RNA; VERAPAMIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVITREAL DRUG ADMINISTRATION; MALE; MULTIDRUG RESISTANCE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VITREORETINOPATHY;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CELL CULTURE TECHNIQUES; CHEMOTHERAPY, ADJUVANT; CHILD, PRESCHOOL; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IMMUNOENZYME TECHNIQUES; KERATINS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PIGMENT EPITHELIUM OF EYE; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 0031964663     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Santana M, Wiedemann P, Kirmani M, et al. Daunomycin in the treatment of experimental proliferative vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit. Graefes Arch Clin Exp Ophthalmol. 1984;221:210-213.
2. Wiedemann P, Leinung C, Hilgers RD, Heimann K. Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1991;229:150-152.
3. Wiedemann P, Lemmen K, Schmiedl R, Heimann K. Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy. Am J Ophthalmol. 1987;104:10-14.
4. Wiedemann P, Sorgente N, Bekhor C, Patterson R, Tran T, Ryan SJ. Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo. Invest Ophthalmol Vis Sci. 1985;26:719-725.
5. Borhani H, Peyman GA, Rahimy MH, Thompson H. Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU. Int Ophthalmol. 1995;19:43-49.
6. Ward T, Hartzer M, Blumenkranz M, Lin LR. A comparison of 5-fluorouridine and 5-fluorouracil in an experimental model for the treatment of vitreoretinal scarring. Curr Eye Res. 1993;12:397-401.
7. Blankenship GW. Evaluation of a single intravitreal injection of 5-fluorouracil in vitrectomy cases. Graefes Arch Clin Exp Ophthalmol. 1989;227:565-568.
8. Hartzer MK, Blumenkranz MS, Hajek AS, Dailey WA, Cheng M, Margherio AR. Selection of therapeutic agents for intraocular pro liferative disease. 3 Effects of fluoropyrimidines on cell-mediated contraction of human fibroblasts. Exp Eye Res. 1989;48:321-328.
9. Chin KV, Pastan I, Gottesman MM. Function and regulation of the human multidrug resistance gene. Adv Cancer Res. 1993;60:157-180.
10. Patel NH, Rothenberg ML. Multidrug resistance in cancer chemotherapy. Invest New Drugs. 1994;12:1-13.
11. Harrison DJ. Molecular mechanisms of drug resistance in tumours. J Pathol. 1995;175:7-12.
12. Lehnen M. Multidrug resistance in human cancer. J Neurooncol. 1994;22:239-243.
13. Preisler HD. Multidrug resistance is more than MDR1 activity. Leuk Res. 1995;19:429-431.
14. Roninson IB. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol. 1992;43:95-102.
15. Machemer R, van Horn D, Aaberg TM. Pigment epithelial proliferation in human retinal detachment with massive periretinal proliferation. Am J Ophthalmol. 1978;85:181-191.
16. Esser P, Heimann K, Wiedemann P. Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations. Br J Ophthalmol. 1993;77:731-733.
17. Esser P, Weller M, Bresgen M, Heimann K, Wiedemann P. The effects of basic fibroblast growth factor on bovine retinal pigment epithelium in vitro. Ger J Ophthalmol. 1992;1:58-61.
18. Esser P, Bresgen M, Weller M, Heimann K, Wiedemann P. The significance of vitronectin in proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 1994;232:477-481.
19. Weller M, Esser P, Heimann K, Wiedemann P. Mononuclear phagocytes in proliferative vitreoretinopathy (PVR). A specific role of microglial cells in non-traumatic disease? Eur J Ophthalmol. 1991; 1:161-166.
20. Lampidis TJ, Krishan A, Planas L, Tapiero H. Reversal of intrinsic resistance to adriamycin in normal cells by verapamil. Cancer Drug Deliv. 1986;3:251-259.
21. Raderer M, Scheithauer W. Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer. 1993;72:3553-3563.
22. Kessel D, Bottenrill V, Wodinsky I. Uptake and retention of daunomycin by mouse leucemic cells as factors in drug response. Cancer Res. 1968;28:938-941.
23. Dano K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta. 1973;323:466-483.
24. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta. 1976;455:152-162.
25. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA. 1987;84:3004-3008.
26. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem. 1989;37:159-164.
27. Lum BL, Gosland MP. Mdr expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am. 1995;9:319-336.
28. Wiedemann P, Kirmani M, Santana M, Sorgente N, Ryan SJ. Control of experimental massive periretinal proliferation by daunomycin: dose-response relation. Graefes Arch Clin Exp Ophthalmol. 1983; 220:233-235.
29. Abe T, Hasegawa S, Taniguchi K, et al. Possible involvement of multidrug-resistance-associated protein (mrp) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells. Int J Cancer. 1994;58:860-864.
30. Weller M, Wiedemann P, Heimann K. Proliferative vitreoretinopathy - is it anything more than wound healing at the wrong place? Int Ophthalmol. 1990;14:105-117.
31. Wang SJ, Scavetta R, Lenz HJ, Danenberg K, Danenberg PV, Schonthal AH. Gene amplification and multidrug resistance induced by the phosphatase-inhibitory tumor promoter, okadaic acid. Carcinogenesis. 1995;16:637-641.
32. Willingham MC, Cornwell MM, Cardarelli CO, Gottesman MM, Pastan I. Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive kb cells: effects of verapamil and other drugs. Cancer Res. 1986;46:5941-5946.
33. Merlin JL, Marchai S, Ramacci C, Notter D, Vigneron C. Modulation of daunorubicin intracellular accumulation in P-glycoprotein expressing MCF-7 human breast adenocarcinoma cells by thermosensitive-liposome encapsulation and hyperthermia. Int J Hyperthermia. 1995;11:855-865.
34. Wiedemann P, Heimann K. Toxicity of intraocular daunomycin. Lens Eye Toxic Res. 1990;7:305-310.
35. Hwang M, Ahn CH, Pine PS, et al. Effect of combination of sub-optimal concentrations of P-glycoprotein blockers on the proliferation of MDR1 gene expressing cells. Int J Cancer. 1996;65:389-397.
36. van Bockxmeer FM, Martin CE, Thompson DE, Constable IJ. Taxol for the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1985;26:1140-1147.
37. Lemor M, de Bustros S, Glaser BM. Low-dose colchicine inhibits astrocyte, fibroblast, and retinal pigment epithelial cell migration and proliferation. Arch Ophthalmol. 1986;104:1223-1225.
38. Steinhorst UH, Chen EP, Machemer R, Hatchell DL. N,n-dimethyl-adriamycin for treatment of experimental proliferative vitreoretinopathy: efficacy and toxicity on the rabbit retina. Exp Eye Res. 1993;56:489-495.
39. Blumenkranz MS, Hartzer MK, Hajek AS. Selection of therapeutic agents for intraocular proliferative disease. II. Differing antiproliferative activity of the fluoropyrimidines. Arch Ophthalmol. 1987; 105:396-399.
40. Salah-Eldin M, Peyman GA, el-Aswad M, Bandok B, Bahgat MM, Niesman MR. Evaluation of toxicity and efficacy of a combination of antineoplastic agents in the prevention of pvr. Int Ophthalmol. 1994;18:53-60.
41. Arroyo MH, Refojo MF, Araiz JJ, Tolentino FI, Cajita VN, Einer VM. Silicone oil as a delivery vehicle for bcnu in rabbit proliferative vitreoretinopathy. Retina. 1993;13:245-250.
42. Heimann K, Wiedemann P. Cologne classification of proliferative vitreoretinopathy. In: Heimann K, Wiedemann P, eds. Proliferative Vitreoretinopathy. Heidelberg: Kaden; 1989:148-149.
43. Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112:159-165.